Arthritis Clinical Trials in Phoenix
View 69 new treatments for Arthritis in Phoenix, AZ, and nearby areas, such as Chandler, Gilbert, Glendale, Mesa, Scottsdale and Surprise. Every day, Power helps hundreds of arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Wharton's Jelly Injections for Knee Osteoarthritis
R3 Clinic, Scottsdale + 1 more
This is a Pilot Study which is randomized, prospective, open label, dose escalation, non-controlled evaluating safety and feasibility of intra-articular Wharton's Jelly (WJ) allograft will be evaluated in patients suffering with knee osteoarthritis. The participants will be randomized to one of three dosing treatment arms that will consist of one intra-articular knee injection containing either low dose, medium dose or high dose WJ allograft tissue.Show More
Recruiting
No Placebo Trial
Phase < 1
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis
Eli Lilly Clinic, Peoria + 5 more
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
COVID-19 VaccinE Response in Rheumatology Patients
Research Clinic, Phoenix + 1 more
This trial tests an extra dose of the COVID-19 vaccine in patients with autoimmune diseases. It aims to see if pausing their medications temporarily can make the vaccine more effective. The goal is to improve their immune response to COVID-19.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 5 - 8 Weeks
Jeffrey R Curtis, MD MS MPH
Principal Investigator
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Sun City + 8 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
COVID-19 Vaccines for Rheumatic Diseases
Research Clinic, Peoria + 1 more
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Baricitinib for Rheumatoid Arthritis
Eli Lilly Clinic, Peoria + 7 more
This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, Phoenix + 4 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
David W Romness, MD
Principal Investigator
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Phoenix + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
UCB Cares
Study Director
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Gilbert + 4 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Axial Spondyloarthritis
AbbVie Clinic, Phoenix + 1 more
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently. The main objectives of this protocol are: * To evaluate the efficacy of upadacitinib compared with placebo on reduction of signs and symptoms in adults with active axial spondyloarthritis (axSpA) including biologic disease-modifying antirheumatic drug inadequate responders (bDMARD-IR) ankylosing spondylitis (AS) (Study 1) and non-radiographic axial spondyloarthritis (nr-axSpA) (Study 2). * To assess the safety and tolerability of upadacitinib in adults with active axSpA including bDMARD-IR AS (Study 1) and nr-axSpA (Study 2). * To evaluate the safety and tolerability of upadacitinib in extended treatment in adult participants with active axSpA including bDMARD-IR AS who have completed the Double-Blind Period (Study 1) and nr-axSpA who have completed the Double-Blind Period (Study 2). * To evaluate the maintenance of disease control after withdrawal of upadacitinib.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
Page 1 of 6
Frequently Asked Questions
Explore related conditions